Given that the translocation of FOXO3a into the nucleus by AKT inhibitors is a current limitation for treating CRC patients with a high expression of nucleus β-catenin [17,19], we aimed to test whether KY1022, a small molecule inhibiting EMT of CRC cells via the destabilization of β-catenin, overcomes the API-2-induced cell migration ability of CRC cells. The gene discussed is AKT1; the disease is colorectal carcinoma.